Browse our latest Cancer Biology articles

Page 91 of 94
    1. Cell Biology
    2. Cancer Biology

    BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function

    Xuetian Yue, Yuhan Zhao ... Wenwei Hu
    Overexpression of BAG2—a novel mutant p53 binding protein—in tumors inhibits MDM2-mediated mutant p53 degradation, which leads to the accumulation of mutant p53 protein and promotes tumorigenesis.
    1. Developmental Biology
    2. Cancer Biology

    The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma

    Nathan M Krah, Jean-Paul De La O ... L Charles Murtaugh
    By regulating acinar cell differentiation, the transcription factor PTF1A acts as a novel class of tumor suppressor in pancreatic cancer.
    1. Developmental Biology
    2. Cancer Biology

    MicroRNA-203 represses selection and expansion of oncogenic Hras transformed tumor initiating cells

    Kent Riemondy, Xiao-jing Wang ... Rui Yi
    Inhibition of microRNA-203 by oncogenic HRas mutations promotes skin cancer initiation.
    1. Developmental Biology
    2. Cancer Biology

    Pancreatic Cancer: Change isn't always better

    Heather Schofield, Marina Pasca di Magliano
    Version of Record
    Insight
    1. Cancer Biology

    KRAS-dependent sorting of miRNA to exosomes

    Diana J Cha, Jeffrey L Franklin ... James G Patton
    In isogenically matched colorectal cancer (CRC) cell lines, mutant KRAS alters the composition of secreted miRNAs in extracellular vesicles that can then transfer repressive activity to wild type cells.
    1. Cancer Biology

    Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

    Arun M Unni, William W Lockwood ... Harold Varmus
    Co-mutation of two powerful oncogenes in certain cell types may have a lethal effect that explains the mutual exclusivity of the mutations.
    1. Cancer Biology

    A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

    Sébastien Jeay, Swann Gaulis ... Diana Graus Porta
    The discovery and preclinical validation of a novel gene signature predictive for response to HDM2-targeting drug NVP-CGM097 could significantly improve the clinical response rate to all p53-HDM2 inhibitors.
    1. Cancer Biology

    Translational Oncology: A signature for success

    Joaquín M Espinosa, Kelly D Sullivan
    Version of Record
    Insight
    1. Cell Biology
    2. Cancer Biology

    Increased H+ efflux is sufficient to induce dysplasia and necessary for viability with oncogene expression

    Bree K Grillo-Hill, Changhoon Choi ... Diane L Barber
    Increasing the internal pH of cells can induce dysplasia and enhance oncogene-increased cell growth, while decreasing the internal pH combined with oncogene expression leads to synthetic lethality.
    1. Cancer Biology

    Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

    S Michael Rothenberg, Kyle Concannon ... Daniel A Haber
    SOX2 causes resistance to anti-EGFR therapies in EGFR-mutant lung cancer.